Want to jump on the bandwagon of buying investment products linked to AI? Why might putting your money on the latest investments themes not be the best idea?  Michelle Martin finds out with Christopher Tan, CEO, Providend. 

Want to jump on the bandwagon of buying investment products linked to AI? Why might putting your money on the latest investments themes not be the best idea?  Michelle Martin finds out with Christopher Tan, CEO, Providend.

Start your day on a positive note with Live Well with Michelle Martin.

The show explores wellbeing in all its dimensions — from self-awareness and personal growth to money, investing, and everyday lifestyle. Through thoughtful interviews and engaging conversations, Michelle speaks with experts and changemakers on living and ageing well, while helping you discover new ideas — from great books on READ and inspiring voices on INFLUENCE, to practical financial insights on MONEY AND ME.

In a fast-moving world that can often feel overwhelming, Live Well offers a refreshing counterpoint — with insights, ideas and stories that help you feel informed, empowered and ready to take on the day.

Start your day on a positive note with Live Well with Michelle Martin.
The show explores wellbeing in all its dimensions &mdash; from self-awareness and personal growth to money, investing, and everyday lifestyle. Through thoughtful interviews and engaging conversations, Michelle speaks with experts and changemakers on living and ageing well, while helping you discover new ideas &mdash; from great books on READ and inspiring voices on INFLUENCE, to practical financial insights on MONEY AND ME.
In a fast-moving world that can often feel overwhelming, Live Well offers a refreshing counterpoint &mdash; with insights, ideas and stories that help you feel informed, empowered and ready to take on the day.

Live Well with Michelle

Michelle Martin speaks with financial advisors on how to make the most of your money. Learn how to get started,  manage your expenses and start your smart money investment journey today. 

Michelle Martin speaks with financial advisors on how to make the most of your money. Learn how to get started,&nbsp; manage your expenses and start your smart money investment journey today.&nbsp;

Money and Me

MONEY FM 89.3 is Singapore’s first and only Business and Personal Finance station. MONEY FM is a 24-hour English talk format station featuring local and international business and financial news. We provide you with financial market and currency updates and insights from analysts, economists, policy makers, industry experts and business owners.

In the lighter hours, listen to discussions on social issues and features on topics that include health, education, arts and music.

MONEY FM 89.3 is Singapore&rsquo;s first and only Business and Personal Finance station. MONEY FM is a 24-hour English talk format station featuring local and international business and financial news. We provide you with financial market and currency updates and insights from analysts, economists, policy makers, industry experts and business owners.
In the lighter hours, listen to discussions on social issues and features on topics that include health, education, arts and music.

MONEY FM 89.3 is Singapore’s first and only Business and Personal Finance station.

MONEY FM 89.3

Start your day on a positive note with Live Well with Michelle Martin.

Live Well with Michelle (10am to 1pm)

Money and Me: Hearing AI investment products being talked up? Here's how to look beyond hype

Is the recent market turbulence creating buying opportunities?

Michelle Martin looks at Bank of America’s call on Nvidia and other stocks it believes are now attractively priced, as bond-market warning signals loom over a new trading week.

Plus, the battle for the obesity-drug market intensifies as Novo Nordisk searches for its next growth chapter against Eli Lilly, while another pharma stock rockets on an injectables deal with the Wegovy maker.

In Up or Down, why has Microsoft climbed back to its highest close of 2026, why did the launch of the long-awaited Tesla Semi fail to excite investors, and what are insider buying and a bigger share-buyback programme telling us about Singapore-listed Nam Cheong and Seatrium?

And in the Last Word: Avengers: Endgame returns to cinemas - and seven years later, Earth's mightiest heroes are back on top at the box office.

Is the recent market turbulence creating buying opportunities?
Michelle Martin looks at Bank of America&rsquo;s call on Nvidia and other stocks it believes are now attractively priced, as bond-market warning signals loom over a new trading week.
Plus, the battle for the obesity-drug market intensifies as&nbsp;Novo Nordisk&nbsp;searches for its next growth chapter against&nbsp;Eli Lilly, while another pharma stock rockets on an injectables deal with the Wegovy maker.
In&nbsp;Up or Down, why has&nbsp;Microsoft&nbsp;climbed back to its highest close of 2026, why did the launch of the long-awaited&nbsp;Tesla Semi&nbsp;fail to excite investors, and what are insider buying and a bigger share-buyback programme telling us about Singapore-listed&nbsp;Nam Cheong and Seatrium?
And in the Last Word:&nbsp;Avengers: Endgame returns to cinemas - and seven years later, Earth's mightiest heroes are back on top at the box office.

Market View: Nvidia on Sale? Novo vs Lilly, Microsoft’s Comeback and Tesla’s Semi Problem

Singapore declared war on diabetes a decade ago, yet the condition still affects around one in eleven adults, while rising obesity adds to concerns about Type 2 diabetes.

Michelle Martin speaks with Dr Anuradha Negi, Senior Consultant Endocrinologist at the Aspen Diabetes & Endocrine Clinic, about what everyone should understand about Type 1 and Type 2 diabetes, who is most at risk, and the practical steps that can help prevent or better manage the condition.

They also examine the growing role of continuous glucose monitoring (CGM).

How much more can a sensor reveal compared with a finger-prick test? Who benefits most from having glucose readings throughout the day?

And with CGM currently subsidised in Singapore for eligible patients with Type 1 and certain rarer forms of diabetes, could some people with Type 2 diabetes benefit from wider access?

Plus, Dr Negi explains the limitations of CGM, when traditional glucose testing may still be necessary, and what good diabetes management looks like beyond medication.

Singapore declared war on diabetes a decade ago, yet the condition still affects around one in eleven adults, while rising obesity adds to concerns about Type 2 diabetes.
Michelle Martin speaks with Dr Anuradha Negi, Senior Consultant Endocrinologist at the Aspen Diabetes &amp; Endocrine Clinic, about what everyone should understand about Type 1 and Type 2 diabetes, who is most at risk, and the practical steps that can help prevent or better manage the condition.
They also examine the growing role of continuous glucose monitoring (CGM).
How much more can a sensor reveal compared with a finger-prick test? Who benefits most from having glucose readings throughout the day?
And with CGM currently subsidised in Singapore for eligible patients with Type 1 and certain rarer forms of diabetes, could some people with Type 2 diabetes benefit from wider access?
Plus, Dr Negi explains the limitations of CGM, when traditional glucose testing may still be necessary, and what good diabetes management looks like beyond medication.

Diabetes in Singapore: Who Really Needs a Continuous Glucose Monitor?

CPF savings in the Special, MediSave and Retirement Accounts will continue to enjoy a 4% interest rate floor until the end of 2027. But what does that mean for the money you have outside CPF?

Michelle Martin speaks with Elijah Lee, Senior Financial Services Manager at Phillip Securities, about how investors should weigh CPF’s relatively attractive returns against liquidity and the potential for higher investment returns elsewhere.

They discuss whether CPF should be viewed as part of your overall portfolio, whether having a secure CPF base gives you room to take more risk outside it, and why comparing CPF’s 4% directly with REIT, dividend-stock or bond yields can be misleading.

Plus, when might investing your CPF savings make sense, how should the equation change as you approach 55, and who should think twice before locking more money away in CPF?

CPF savings in the Special, MediSave and Retirement Accounts will continue to enjoy a 4% interest rate floor until the end of 2027. But what does that mean for the money you have outside CPF?
Michelle Martin speaks with Elijah Lee, Senior Financial Services Manager at Phillip&nbsp;Securities,&nbsp;about how investors should weigh CPF&rsquo;s relatively attractive returns against liquidity and the potential for higher investment returns elsewhere.
They discuss whether CPF should be viewed as part of your overall portfolio, whether having a secure CPF base gives you room to take more risk outside it, and why comparing CPF&rsquo;s 4% directly with REIT, dividend-stock or bond yields can be misleading.
Plus, when might investing your CPF savings make sense, how should the equation change as you approach 55, and who should think twice before locking more money away in CPF?

Money and Me: Hearing AI investment products being talked up? Here's how to look beyond hype

In 3 playlist(s)

Live Well with Michelle (10am to 1pm)

Social links

Follow podcast

Recent clips